Evonik Industries AG (ETR:EVK)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.17B -0.6% |
| Revenue (ttm) | 13.72B -9.4% |
| Net Income | 157.00M -47.5% |
| EPS | 0.34 -47.6% |
| Shares Out | 466.00M |
| PE Ratio | 51.98 |
| Forward PE | 10.41 |
| Dividend | 1.00 (5.70%) |
| Ex-Dividend Date | Jun 4, 2026 |
| Volume | 1,462,820 |
| Open | 17.55 |
| Previous Close | 17.55 |
| Day's Range | 17.47 - 17.74 |
| 52-Week Range | 12.49 - 18.25 |
| Beta | 0.53 |
| Analysts | Hold |
| Price Target | 17.93 (+2.22%) |
| Earnings Date | Aug 4, 2026 |
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and ... [Read more]
Financial Performance
In 2025, Evonik Industries AG's revenue was 14.07 billion, a decrease of -7.18% compared to the previous year's 15.16 billion. Earnings were 265.00 million, an increase of 19.37%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EVK stock is "Hold." The 12-month stock price target is €17.93, which is an increase of 2.22% from the latest price.
News
Evonik Industries AG: Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
Meets the growing demand for U.S.-based contract development and manufacturing organizations (CDMOs)Further improves capabilities to handle increasing complexity of active pharmaceutical ingredien...
Evonik Raises Performance Outlook Amid Supply Chain Disruptions
Evonik Raises Performance Outlook Amid Supply Chain Disruptions
Evonik Raises Guidance on Higher Prices, Cost Reductions
Evonik said it raised its guidance for the year on higher prices, higher sales volumes and cost reductions.
Evonik Industries: Q2 2026 financials and adjusted outlook for 2026
Evonik lifts its 2026 outlook as strong Q2 earnings, robust volumes and pricing, and supply-chain tailwinds fuel confidence—despite rising uncertainty for H2.
EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Forecast / Full year/Results / Half year Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the ...
Evonik Industries AG Transcript: Investor update
Resilience, sustainability, and innovation are integrated to address global challenges and drive growth. Key initiatives include advanced biosolutions, green hydrogen, and circular economy solutions, supported by a restructured R&D organization and international hubs.
Evonik Industries AG Transcript: AGM 2026
The meeting addressed leadership changes, a challenging financial year, and a shift to a performance-based dividend policy. Strategic initiatives focus on innovation, cost discipline, and green transformation, with continued investment in growth areas.
Evonik Industries AG Earnings Call Transcript: Q1 2026
Q1 2026 adjusted EBITDA exceeded expectations at EUR 475 million, driven by strong Advanced Technologies and pre-buying effects, while free cash flow remained robust. Q2 EBITDA is guided to at least EUR 550 million, but risks from inflation and supply chain disruptions persist.
Evonik Industries AG Slides: Q1 2026
Evonik Industries AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Evonik Industries AG Quarterly report: Q1 2026
Evonik Industries AG has published its Q1 2026 quarterly earnings report on May 8, 2026.
Evonik Industries AG Earnings release: Q1 2026
Evonik Industries AG released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Company presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Evonik Industries AG Earnings release: Q4 2025
Evonik Industries AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Evonik Industries AG Annual report: Q4 2025
Evonik Industries AG has published its Q4 2025 annual report on March 4, 2026.
Evonik Industries AG Annual report: Q4 2025
Evonik Industries AG has published its Q4 2025 annual report on March 4, 2026.
Evonik Industries AG Slides: Q4 2025
Evonik Industries AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Slides: Sustainability presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Slides: Investor presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Earnings Call Transcript: Q4 2025
Delivered solid 2025 results with EUR 1.9 billion adjusted EBITDA and strong cash flow. 2026 guidance targets stable earnings amid persistent weak demand, cost savings, and a new flexible dividend policy. Regulatory and market changes, especially in methionine and Oxeno, will shape performance.
Evonik Industries AG Earnings release: Q4 2025
Evonik Industries AG released its Q4 2025 earnings on February 5, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Q4 2025
Evonik Industries AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Evonik Industries AG Earnings Call Transcript: Q3 2025
Q3 results were weak, leading to a revised full-year EBITDA guidance of EUR 1.9 billion, but confidence remains in meeting targets due to strong healthcare and Animal Nutrition recovery. Structural cost savings, new plant ramp-ups, and the SYNEQT carve-out are expected to support future performance despite ongoing market challenges.
Evonik Industries AG Quarterly report: Q3 2025
Evonik Industries AG has published its Q3 2025 quarterly earnings report on November 4, 2025.
Evonik Industries AG Slides: Q3 2025
Evonik Industries AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
Evonik Industries AG Earnings Call Transcript: Q2 2025
Q2 results were resilient despite macro headwinds, with core segments stable and cost savings underway. Full-year guidance is maintained at the lower end, but achieving it depends on macro improvement and strict cost controls.